TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00915070

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann Applanation Tonometer
Description: intraocular pressure measurements

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Goldmann Applanation Tonometer
Description: intraocular pressure measurements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: squatting
Description: subjects will perform squatting for 6 minutes while blood flow measurements

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: squatting
Description: subjects will perform squatting for 6 minutes while blood flow measurements
Study: NCT00136903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochymal® - 2 Million cells/kg
Description: 2 million hMSCs/kg actual body weight, IV on study Days 1 and 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochymal®- 8 Million cells/kg
Description: 8 million hMSCs/kg actual body weight IV on study Days 1 and 4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 2 mg/kg administered intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 2 mg/kg administered intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 2.5 mg/kg administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 2.5 mg/kg administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Administered as prescribed by the caregiver.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Administered as prescribed by the caregiver.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Administered as prescribed by the caregiver.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Administered as prescribed by the caregiver.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Administered as prescribed by the caregiver.
Study: NCT00328198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered SC at alternating injection sites 3 times per week for up to 18 weeks.~Part 2 of the study: All patients are currently being enrolled under the no escalation schedule for Part 2 of the study. All patients in Part 2 will be treated with 30mg of alemtuzumab (with no escalation period) administered SC (at alternating injection sites) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 18 weeks. Alemtuzumab is to be administered in a supervised medical setting on an outpatient basis for the first three weeks, after which some study centers may allow a home administration option, with one weekly clinic visit. Under the home administration option, alemtuzumab may be administered by the patient or care giver if the patient meets conditions specified in the protocol guidelines for home administration.
Study: NCT02290639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Treatment
Description: Cognitive-behavioral therapy (CBT) protocol designed specifically for use by behavioral health consultants (BHC) working in an integrated primary care setting. The treatment will be provided by a BHC in four 30-minute appointments scheduled approximately once a week in primary care over a one month period. Treatment content was largely drawn from a Prolonged Exposure model, but also includes elements of Cognitive Processing Therapy.
Study: NCT00136903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Administered as prescribed by the caregiver.
Study: NCT02290639

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Cognitive Behavioral Treatment
Description: Cognitive-behavioral therapy (CBT) protocol designed specifically for use by behavioral health consultants (BHC) working in an integrated primary care setting. The treatment will be provided by a BHC in four 30-minute appointments scheduled approximately once a week in primary care over a one month period. Treatment content was largely drawn from a Prolonged Exposure model, but also includes elements of Cognitive Processing Therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Contact
Description: Participants assigned to minimal contact (MC) will be asked to not work with another therapist or seek additional treatment for trauma-related difficulties during the 6-week MC period. They will be called once per week by the Behavioral Health Consultant (BHC) in order to monitor their status and to provide support as needed. The calls will be limited to 5-10 minutes.
Study: NCT01370798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: promestriene
Description: Promestriene cream 1%, 1g per day during 2 months, cutaneous application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of promestriene cream, 1g per day during 2 months, cutaneous application

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Urethroplasty
Description: Onlay-tube-onlay urethroplasty performed by a physician expert of this technique (at least 5 years of practical ability)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urethroplasty
Description: Onlay-tube-onlay urethroplasty performed by a physician expert of this technique (at least 5 years of practical ability)

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Wrist X ray
Description: Wrist X ray to follow the degree of bone maturation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Wrist X ray
Description: Wrist X ray to follow the degree of bone maturation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood test
Description: Hormonal dosage: Oestradiol, testosterone, FSH-LH and AMH

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Hormonal dosage: Oestradiol, testosterone, FSH-LH and AMH
Study: NCT04149327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin 500 mg + metronidazole 500 mg
Description: 500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for 7 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal and peri-implant treatment
Description: Patients are instructed on how to perform proper oral hygiene measures using an electric toothbrush, interdental brushes (to be used in combination with Corsodyl® gel) and floss (Oral-B® superfloss or Meridol® floss, at implants only).~Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned.
Study: NCT02011308

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Green light Laser
Description: Laser vs TURP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Green light Laser
Description: Laser vs TURP
Study: NCT00263458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting
Description: Eligible opioid-dependent HIV-infected patients are randomly assigned to receive buprenorphine opioid agonist treatment for 12 months either in an integrated HIV primary care setting (intervention group) versus a non-integrated substance use treatment clinic setting (comparison group).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting
Description: Eligible opioid-dependent HIV-infected patients are randomly assigned to receive buprenorphine opioid agonist treatment for 12 months either in an integrated HIV primary care setting (intervention group) versus a non-integrated substance use treatment clinic setting (comparison group).
Study: NCT02197416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
Study: NCT02011308

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection of the Prostate (TURP)
Description: Laser vs TURP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection of the Prostate (TURP)
Description: Laser vs TURP
Study: NCT01627847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Study: NCT04279964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Boot Camp Translation
Description: Practices in the intervention arm will participate in the Boot Camp Translation process, where BCT Community Advisory group members will come together to develop and implement practice relevant materials to promote adolescent vaccination.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No intervention. Practices will continue to behave as usual.
Study: NCT02165124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Embolization Device
Description: Embosphere Microspheres
Study: NCT01594658

Intervention type: PROCEDURE
Intervention: Foam sclerotherapy
Description: Foam application of 1% (Sklerol®, ICV Pharma, Bogota-Colombia), Reg INVIMA: 2002M-0001016, guided by ecography of insufficient superficial veins, doses from 10-40 cc of foam until obtaining endoluminal occlusion of the vein. The patient will rest for 8 minutes and then the leg will be covered with elastic bandage.

Intervention type: PROCEDURE
Intervention: conservative
Description: This arm only has medical standard handling (healings performed by the nurse group)
Study: NCT02019433

Intervention type: DEVICE
Intervention: Structan®
Study: NCT01813422

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT04288466

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin
Description: maltodextrin solution 450ml

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin
Description: maltodextrin solution 450ml
Study: NCT02781064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg
Description: Atorvastatin and matching placebo to be taken in a randomised order for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 20mg
Description: Atorvastatin and matching placebo to be taken in a randomised order for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Atorvastatin and matching placebo to be taken in a randomised order for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Atorvastatin and matching placebo to be taken in a randomised order for 12 months
Study: NCT04458389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY101
Description: Dose escalation: TY101 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg 200mg Intravenous Q3W, 2 years depending on response.~Dose expansion: Subjects received TY101 injection for a maximum of 2 years until progressive disease, intolerant toxicity, death, or withdrawal from the study occurred.
Study: NCT01515319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y242
Description: Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y242
Description: Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y242
Description: Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y242
Description: Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y242
Description: Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y242
Description: Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y242
Description: Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y242
Description: Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Identical volume to that of Y242

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Identical volume to that of Y242
Study: NCT00527085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 073
Description: 30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
Study: NCT02773251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid-carboxymethylcellulose
Study: NCT00747929

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S-2367 Placebo
Description: four placebo tablets (total dose = 0 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-2367 800 mg
Description: two 400 mg S-2367 tablets (total dose = 800 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-2367 1600 mg
Description: four 400 mg S-2367 tablets (total dose = 1600 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for total of 54 weeks,
Study: NCT00990574

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wiley Spinal Catheter
Description: The WSCG (wiley spinal catheter group) will have a Wiley spinal catheter placed, but it will not be dosed until the patient is in the supine position with left uterine displacement. Participants will receive the medication (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) in sequential doses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia Group (SAG)
Description: The SAG (spinal anesthesia group) will have their drugs (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) dosed intrathecally as a single shot while still in the sitting position.
Study: NCT04149327

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical periodontal and peri-implant treatment
Description: Patients are instructed on how to perform proper oral hygiene measures using an electric toothbrush, interdental brushes (to be used in combination with Corsodyl® gel) and floss (Oral-B® superfloss or Meridol® floss, at implants only).~Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned.
Study: NCT01646008

Intervention type: OTHER
Intervention: To measure carbon dioxide by capnography and arterial blood
Description: Three times per day will be measured exhaled carbon dioxide and obtained in arterial blood sample.

Intervention type: OTHER
Intervention: to measure carbon dioxide by capnography and arterial blood
Description: three times per day we will obtained arterial blood samples and measurements of carbon dioxide by capnography
Study: NCT03896568

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Adenovirus Ad5-DNX-2401
Description: Given IA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Adenovirus Ad5-DNX-2401
Description: Given IA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT00747929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Calorie Diet
Description: A diet with restricted calorie content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Calorie Diet
Description: A diet with restricted calorie content

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reduced Calorie Diet
Description: A diet with restricted calorie content
Study: NCT02548195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin and gemcitabine
Description: oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2 every three weeks for 6-8 cycles in total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
Study: NCT00083174

Intervention type: DRUG
Group type: OTHER
Intervention: exemestane
Description: one 25 mg tablet daily in am
Study: NCT03092544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl fumarate
Description: Active drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl fumarate
Description: Active drug
Study: NCT02554513

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EPG Tx
Description: behavioral intervention that incorporates a device that provides visual biofeedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPT
Description: A treatment hierarchy involving integral stimulation
Study: NCT02402764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Participants will receive selinexor twice weekly on Monday/Wednesday, Tuesday/Thursday or Wednesday/Friday of Weeks 1, 2 and 3 of each 4-week cycle. Selinexor will not be taken during Week 4. One cycle is defined as 28 days or 6 doses. The starting dose for this trial is 60 mg (flat dose as long as their dose-based body surface area (BSA) analysis does not exceed 70 mg/m\^2).
Study: NCT03704298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert
Study: NCT04266548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superselective Intra-arterial Hepatic Injection of Indocyanine Green (ICG) for Fluorescence Image-guided Segmental Positive Staining
Description: The patients with single HCC which is planned to received laparoscopic hepatectomy were involved. Procedures were performed in conventional angiography room. The celiac trunk was catheterized and a microcatheter was advanced into segmental hepatic artery branches which supplied the HCC. The 5cc 0.125 mg/cc ICG was injected from super-selective hepatic artery in operative room. A Near-Infrared laparoscope was used to detect the fluorescent signal to assess the correspondence between arterial-based fluorescence demarcation and ultrasound-based surgical demarcation.
Study: NCT00804973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2590443
Description: 200 milligrams (mg) as four 50-mg capsules, oral, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo injection
Description: saline solution, injection, once
Study: NCT03704298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
Study: NCT00804973

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: saline solution, injection, once